K Bochennek1, A Balan2, L Müller-Scholden1, M Becker1, F Farowski3, C Müller4, A H Groll5, T Lehrnbecher6. 1. Pediatric Hematology and Oncology, Johann Wolfgang Goethe-University, Frankfurt, Germany. 2. Pediatric Hematology and Oncology, Johann Wolfgang Goethe-University, Frankfurt, Germany 'Victor Babes' University of Medicine and Pharmacy, Timisoara, Romania. 3. Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany. 4. Department of Pharmacology, University Hospital of Cologne, Cologne, Germany. 5. Infectious Disease Research Program, Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology, University Children's Hospital Münster, Münster, Germany. 6. Pediatric Hematology and Oncology, Johann Wolfgang Goethe-University, Frankfurt, Germany thomas.lehrnbecher@kgu.de.
Abstract
BACKGROUND: Current guidelines recommend antifungal prophylaxis for children at high risk for invasive fungal disease (IFD), but the use of polyenes and triazoles may not be feasible in some patients due to toxicities and drug-drug interactions. Micafungin is well tolerated, with intravenous daily dosing being the current standard. Recent reports indicate safety and efficacy of intermittent dosing of micafungin. METHODS: We analysed safety, efficacy and micafungin serum concentrations of children at high risk for IFD receiving prophylactic micafungin between 3 and 4 mg/kg twice weekly. All children were intolerant or had contraindications to polyenes and triazoles. RESULTS: A total of 21 children (median age = 9 years) at high risk for IFD were included in the analysis. No significant clinical adverse event occurred, and end of treatment values of parameters of renal and hepatic function in serum were not different from baseline. Proven or probable breakthrough IFD did not occur in any of the patients. In 9 out of 11 patients in whom plasma micafungin concentrations were assessed, the first trough concentration exceeded 150 ng/mL, a concentration proposed to be effective for prophylaxis. CONCLUSIONS: Our data indicate that micafungin administered twice weekly at a dosage of 3-4 mg/kg of bodyweight could be a convenient, safe and efficient alternative for antifungal prophylaxis in children at high risk for IFD.
BACKGROUND: Current guidelines recommend antifungal prophylaxis for children at high risk for invasive fungal disease (IFD), but the use of polyenes and triazoles may not be feasible in some patients due to toxicities and drug-drug interactions. Micafungin is well tolerated, with intravenous daily dosing being the current standard. Recent reports indicate safety and efficacy of intermittent dosing of micafungin. METHODS: We analysed safety, efficacy and micafungin serum concentrations of children at high risk for IFD receiving prophylactic micafungin between 3 and 4 mg/kg twice weekly. All children were intolerant or had contraindications to polyenes and triazoles. RESULTS: A total of 21 children (median age = 9 years) at high risk for IFD were included in the analysis. No significant clinical adverse event occurred, and end of treatment values of parameters of renal and hepatic function in serum were not different from baseline. Proven or probable breakthrough IFD did not occur in any of the patients. In 9 out of 11 patients in whom plasma micafungin concentrations were assessed, the first trough concentration exceeded 150 ng/mL, a concentration proposed to be effective for prophylaxis. CONCLUSIONS: Our data indicate that micafungin administered twice weekly at a dosage of 3-4 mg/kg of bodyweight could be a convenient, safe and efficient alternative for antifungal prophylaxis in children at high risk for IFD.
Authors: Thomas Lehrnbecher; Konrad Bochennek; Thomas Klingebiel; Silke Gastine; Georg Hempel; Andreas H Groll Journal: Clin Microbiol Rev Date: 2019-05-15 Impact factor: 26.132
Authors: Roeland E Wasmann; Eline W Muilwijk; David M Burger; Paul E Verweij; Catherijne A Knibbe; Roger J Brüggemann Journal: Clin Pharmacokinet Date: 2018-03 Impact factor: 6.447
Authors: Thomas Lehrnbecher; Stefan Schöning; Fiona Poyer; Jamina Georg; Andreas Becker; Kathrin Gordon; Andishe Attarbaschi; Andreas H Groll Journal: Front Microbiol Date: 2019-04-16 Impact factor: 5.640
Authors: Mirjam Esther van de Velde; Gertjan J L Kaspers; Floor C H Abbink; Jos W R Twisk; Inge M van der Sluis; Cor van den Bos; Marry M van den Heuvel-Eibrink; Heidi Segers; Christophe Chantrain; Jutte van der Werff Ten Bosch; Leen Willems; Marleen H van den Berg Journal: Cancers (Basel) Date: 2020-12-12 Impact factor: 6.639